Literature DB >> 31597776

Evaluating the Intactness of Persistent Viral Genomes in Simian Immunodeficiency Virus-Infected Rhesus Macaques after Initiating Antiretroviral Therapy within One Year of Infection.

Samuel Long1, Christine M Fennessey1, Laura Newman1, Carolyn Reid1, Sean P O'Brien1, Yuan Li1, Gregory Q Del Prete1, Jeffrey D Lifson1, Robert J Gorelick1, Brandon F Keele2.   

Abstract

The major obstacle to more-definitive treatment for HIV infection is the early establishment of virus that persists despite long-term combination antiretroviral therapy (cART) and can cause recrudescent viremia if cART is interrupted. Previous studies of HIV DNA that persists despite cART indicated that only a small fraction of persistent viral sequences was intact. Experimental simian immunodeficiency virus (SIV) infections of nonhuman primates (NHPs) are essential models for testing interventions designed to reduce the viral reservoir. We studied the viral genomic integrity of virus that persists during cART under conditions typical of many NHP reservoir studies, specifically with cART started within 1 year postinfection and continued for at least 9 months. The fraction of persistent DNA in SIV-infected NHPs starting cART during acute or chronic infection was assessed with a multiamplicon, real-time PCR assay designed to analyze locations that are regularly spaced across the viral genome to maximize coverage (collectively referred to as "tile assay") combined with near-full-length (nFL) single-genome sequencing. The tile assay is used to rapidly screen for major deletions, with nFL sequence analysis used to identify additional potentially inactivating mutations. Peripheral blood mononuclear cells (PBMC) from animals started on cART within 1 month of infection, sampled at least 9 months after cART initiation, contained at least 80% intact genomes, whereas those from animals started on cART 1 year postinfection and treated for 1 year contained intact genomes only 47% of the time. The most common defect identified was large deletions, with the remaining defects caused by APOBEC-mediated mutations, frameshift mutations, and inactivating point mutations. Overall, this approach can be used to assess the intactness of persistent viral DNA in NHPs.IMPORTANCE Molecularly defining the viral reservoir that persists despite antiretroviral therapy and that can lead to rebound viremia if antiviral therapy is removed is critical for testing interventions aimed at reducing this reservoir. In HIV infection in humans with delayed treatment initiation and extended treatment duration, persistent viral DNA has been shown to be dominated by nonfunctional genomes. Using multiple real-time PCR assays across the genome combined with near-full-genome sequencing, we defined SIV genetic integrity after 9 to 18 months of combination antiretroviral therapy in rhesus macaques starting therapy within 1 year of infection. In the animals starting therapy within a month of infection, the vast majority of persistent DNA was intact and presumptively functional. Starting therapy within 1 year increased the nonintact fraction of persistent viral DNA. The approach described here allows rapid screening of viral intactness and is a valuable tool for assessing the efficacy of novel reservoir-reducing interventions.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  SIV; genome intactness; genomic integrity; persistent viral reservoir; single-genome sequencing

Mesh:

Substances:

Year:  2019        PMID: 31597776      PMCID: PMC6912123          DOI: 10.1128/JVI.01308-19

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

1.  Defective HIV-1 Proviruses Are Expressed and Can Be Recognized by Cytotoxic T Lymphocytes, which Shape the Proviral Landscape.

Authors:  Ross A Pollack; R Brad Jones; Mihaela Pertea; Katherine M Bruner; Alyssa R Martin; Allison S Thomas; Adam A Capoferri; Subul A Beg; Szu-Han Huang; Sara Karandish; Haiping Hao; Eitan Halper-Stromberg; Patrick C Yong; Colin Kovacs; Erika Benko; Robert F Siliciano; Ya-Chi Ho
Journal:  Cell Host Microbe       Date:  2017-04-12       Impact factor: 21.023

2.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.

Authors:  T W Chun; L Stuyver; S B Mizell; L A Ehler; J A Mican; M Baseler; A L Lloyd; M A Nowak; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

3.  Identification of Genetically Intact HIV-1 Proviruses in Specific CD4+ T Cells from Effectively Treated Participants.

Authors:  Bonnie Hiener; Bethany A Horsburgh; John-Sebastian Eden; Kirston Barton; Timothy E Schlub; Eunok Lee; Susanne von Stockenstrom; Lina Odevall; Jeffrey M Milush; Teri Liegler; Elizabeth Sinclair; Rebecca Hoh; Eli A Boritz; Daniel Douek; Rémi Fromentin; Nicolas Chomont; Steven G Deeks; Frederick M Hecht; Sarah Palmer
Journal:  Cell Rep       Date:  2017-10-17       Impact factor: 9.423

4.  Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation.

Authors:  Gero Hütter; Daniel Nowak; Maximilian Mossner; Susanne Ganepola; Arne Müssig; Kristina Allers; Thomas Schneider; Jörg Hofmann; Claudia Kücherer; Olga Blau; Igor W Blau; Wolf K Hofmann; Eckhard Thiel
Journal:  N Engl J Med       Date:  2009-02-12       Impact factor: 91.245

5.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.

Authors:  Pablo Tebas; David Stein; Winson W Tang; Ian Frank; Shelley Q Wang; Gary Lee; S Kaye Spratt; Richard T Surosky; Martin A Giedlin; Geoff Nichol; Michael C Holmes; Philip D Gregory; Dale G Ando; Michael Kalos; Ronald G Collman; Gwendolyn Binder-Scholl; Gabriela Plesa; Wei-Ting Hwang; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2014-03-06       Impact factor: 91.245

6.  A quantitative basis for antiretroviral therapy for HIV-1 infection.

Authors:  Benjamin L Jilek; Melissa Zarr; Maame E Sampah; S Alireza Rabi; Cynthia K Bullen; Jun Lai; Lin Shen; Robert F Siliciano
Journal:  Nat Med       Date:  2012-02-19       Impact factor: 53.440

7.  The Landscape of Persistent Viral Genomes in ART-Treated SIV, SHIV, and HIV-2 Infections.

Authors:  Alexandra M Bender; Francesco R Simonetti; Mithra R Kumar; Emily J Fray; Katherine M Bruner; Andrew E Timmons; Katherine Y Tai; Katharine M Jenike; Annukka A R Antar; Po-Ting Liu; Ya-Chi Ho; Dana N Raugi; Moussa Seydi; Geoffrey S Gottlieb; Afam A Okoye; Gregory Q Del Prete; Louis J Picker; Joseph L Mankowski; Jeffrey D Lifson; Janet D Siliciano; Greg M Laird; Dan H Barouch; Janice E Clements; Robert F Siliciano
Journal:  Cell Host Microbe       Date:  2019-07-10       Impact factor: 31.316

8.  Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy.

Authors:  Christine M Fennessey; Mykola Pinkevych; Taina T Immonen; Arnold Reynaldi; Vanessa Venturi; Priyanka Nadella; Carolyn Reid; Laura Newman; Leslie Lipkey; Kelli Oswald; William J Bosche; Matthew T Trivett; Claes Ohlen; David E Ott; Jacob D Estes; Gregory Q Del Prete; Jeffrey D Lifson; Miles P Davenport; Brandon F Keele
Journal:  PLoS Pathog       Date:  2017-05-04       Impact factor: 6.823

9.  Persistent Viral Reservoirs in Lymphoid Tissues in SIV-Infected Rhesus Macaques of Chinese-Origin on Suppressive Antiretroviral Therapy.

Authors:  Summer Siddiqui; Stefanie Perez; Yong Gao; Lara Doyle-Meyers; Brian T Foley; Qingsheng Li; Binhua Ling
Journal:  Viruses       Date:  2019-01-27       Impact factor: 5.048

10.  Defective proviruses rapidly accumulate during acute HIV-1 infection.

Authors:  Katherine M Bruner; Alexandra J Murray; Ross A Pollack; Mary G Soliman; Sarah B Laskey; Adam A Capoferri; Jun Lai; Matthew C Strain; Steven M Lada; Rebecca Hoh; Ya-Chi Ho; Douglas D Richman; Steven G Deeks; Janet D Siliciano; Robert F Siliciano
Journal:  Nat Med       Date:  2016-08-08       Impact factor: 53.440

View more
  16 in total

1.  Antibody-mediated depletion of viral reservoirs is limited in SIV-infected macaques treated early with antiretroviral therapy.

Authors:  Adrienne E Swanstrom; Taina T Immonen; Kelli Oswald; Cathi Pyle; James A Thomas; William J Bosche; Lorna Silipino; Michael Hull; Laura Newman; Vicky Coalter; Adam Wiles; Rodney Wiles; Jacob Kiser; David R Morcock; Rebecca Shoemaker; Randy Fast; Matthew W Breed; Joshua Kramer; Duncan Donohue; Tyler Malys; Christine M Fennessey; Charles M Trubey; Claire Deleage; Jacob D Estes; Jeffrey D Lifson; Brandon F Keele; Gregory Q Del Prete
Journal:  J Clin Invest       Date:  2021-03-15       Impact factor: 14.808

2.  HIV Reservoirs: Modeling, Quantification, and Approaches to a Cure.

Authors:  Amir Dashti; Vidisha Singh; Ann Chahroudi
Journal:  Methods Mol Biol       Date:  2022

3.  Predictors of SIV recrudescence following antiretroviral treatment interruption.

Authors:  Mykola Pinkevych; Christine M Fennessey; Deborah Cromer; Carolyn Reid; Charles M Trubey; Jeffrey D Lifson; Brandon F Keele; Miles P Davenport
Journal:  Elife       Date:  2019-10-25       Impact factor: 8.140

Review 4.  Eliminating HIV reservoirs for a cure: the issue is in the tissue.

Authors:  Kathleen Busman-Sahay; Carly E Starke; Michael D Nekorchuk; Jacob D Estes
Journal:  Curr Opin HIV AIDS       Date:  2021-07-01       Impact factor: 4.061

5.  Single-Cell Profiling of Latently SIV-Infected CD4+ T Cells Directly Ex Vivo to Reveal Host Factors Supporting Reservoir Persistence.

Authors:  Andrey Tokarev; Kawthar Machmach; Matthew Creegan; Dohoon Kim; Michael A Eller; Diane L Bolton
Journal:  Microbiol Spectr       Date:  2022-05-05

6.  Development and optimization of a simian immunodeficiency virus (SIV) droplet digital PCR (ddPCR) assay.

Authors:  Samuel Long; Brian Berkemeier
Journal:  PLoS One       Date:  2020-10-09       Impact factor: 3.240

7.  Development of a reverse transcription droplet digital PCR (RT-ddPCR) assay for sensitive detection of simian immunodeficiency virus (SIV).

Authors:  Samuel Long; Brian Berkemeier
Journal:  Virol J       Date:  2021-02-15       Impact factor: 4.099

8.  Transient viral replication during analytical treatment interruptions in SIV infected macaques can alter the rebound-competent viral reservoir.

Authors:  Taina T Immonen; Christine M Fennessey; Leslie Lipkey; Abigail Thorpe; Gregory Q Del Prete; Jeffrey D Lifson; Miles P Davenport; Brandon F Keele
Journal:  PLoS Pathog       Date:  2021-06-18       Impact factor: 6.823

9.  Therapeutic vaccination of SIV-infected, ART-treated infant rhesus macaques using Ad48/MVA in combination with TLR-7 stimulation.

Authors:  Katherine M Bricker; Veronica Obregon-Perko; Ferzan Uddin; Brianna Williams; Emilie A Uffman; Carolina Garrido; Genevieve G Fouda; Romas Geleziunas; Merlin Robb; Nelson Michael; Dan H Barouch; Ann Chahroudi
Journal:  PLoS Pathog       Date:  2020-10-26       Impact factor: 6.823

10.  Simian-Human Immunodeficiency Virus SHIV.C.CH505 Persistence in ART-Suppressed Infant Macaques Is Characterized by Elevated SHIV RNA in the Gut and a High Abundance of Intact SHIV DNA in Naive CD4+ T Cells.

Authors:  Veronica Obregon-Perko; Katherine M Bricker; Gloria Mensah; Ferzan Uddin; Mithra R Kumar; Emily J Fray; Robert F Siliciano; Nils Schoof; Anna Horner; Maud Mavigner; Shan Liang; Thomas Vanderford; Julian Sass; Cliburn Chan; Stella J Berendam; Katharine J Bar; George M Shaw; Guido Silvestri; Genevieve G Fouda; Sallie R Permar; Ann Chahroudi
Journal:  J Virol       Date:  2020-12-22       Impact factor: 6.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.